AC Immune SA (ACIU) has released an update.
AC Immune SA is poised to make significant strides in the neurodegenerative disease sector, announcing progress in its pipeline with a landmark deal with Takeda and advancements in active immunotherapies for Alzheimer’s and Parkinson’s diseases. The company has successfully raised USD 50 million to extend its cash runway into 2026, reinforcing its balance sheet. AC Immune spotlights its innovative approach to precision medicine with its upcoming Annual General Meeting in 2024, where it will discuss its financial statements and future strategies.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.
